Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7906858 | 1.00 | FFAR4 (0.44) | FFAR4FFAR1MEN1KMT2AFAAH | |
| SCHEMBL7906844 | 0.85 | MEN1 (0.44) | FFAR4FFAR1MEN1KMT2AFAAH | |
| SCHEMBL21012244 | 0.81 | FNTA (0.47) | MEN1KMT2AFAAHCES2 | |
| SCHEMBL5065774 | 0.81 | FNTA (0.47) | MEN1KMT2AFAAHCES2 | |
| SCHEMBL13253388 | 0.81 | FNTA (0.47) | MEN1KMT2AFAAHCES2 | |
| Glycerin SCHEMBL31612487 | 0.80 | FFAR1 (0.54) | FFAR4FFAR1MEN1KMT2AFAAH | |
| Glycerin SCHEMBL22400733 | 0.80 | FFAR1 (0.54) | FFAR4FFAR1MEN1KMT2AFAAH | |
| SCHEMBL13253389 | 0.80 | FNTA (0.49) | MEN1KMT2AFAAHCES2 | |
| SCHEMBL3837639 | 0.79 | FFAR4 (0.46) | FFAR4FFAR1MEN1KMT2AKDM4E | |
| SCHEMBL14655966 | 0.79 | FFAR4 (0.45) | FFAR4FFAR1MEN1KMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4748164-B2 | — | — | 2011-08-17 | — | — | JP | claimed |
| EP-1807067-A1 | SPHINGOSINE KINASE ACTIVATOR AND SKIN DISEASE TREATING AGENT COMPRISING THE SAME | Neopharm Co., Ltd. (KR) | 2007-07-18 | — | — | EP | claimed |
| WO-2006049404-A1 | SPHINGOSINE KINASE ACTIVATOR AND SKIN DISEASE TREATING AGENT COMPRISING THE SAME | NEOPHARM CO., LTD. (KR) | 2006-05-11 | — | — | WO | claimed |
| US-20060094790-A1 | Use of sphingosine kinase activator as skin disease treating agent and method for treating skin diseases using the same | NEOPHARM CO., LTD. (KR) | 2006-05-04 | — | — | US | claimed |
| EP-1807067-A1 | SPHINGOSINE KINASE ACTIVATOR AND SKIN DISEASE TREATING AGENT COMPRISING THE SAME | Neopharm Co., Ltd. (KR) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006049404-A1 | SPHINGOSINE KINASE ACTIVATOR AND SKIN DISEASE TREATING AGENT COMPRISING THE SAME | NEOPHARM CO., LTD. (KR) | 2006-05-11 | — | — | WO | disclosed |
| US-20060094790-A1 | Use of sphingosine kinase activator as skin disease treating agent and method for treating skin diseases using the same | NEOPHARM CO., LTD. (KR) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094790-A1 | Use of sphingosine kinase activator as skin disease treating agent and method for treating skin diseases using the same | SPHK1, SPHK2, S1PR1 | FFAR4 671/4885FFAR1 600/4885MEN1 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.